Leadership changes at one of the world's largest and most underappreciated biotechs bode well for investors.
The acquisition is a vote of confidence in Isis Pharmaceuticals' drug development technology.
The biopharmaceutical company's core product strategy is aimed at addressing major unmet medical needs.
These small-cap biotechs have just confirmed bottom formations, setting up good buying opportunities on pullbacks.
But a few are more likely to sell than others. Here are some names.
The two drug companies end a rocky 10-year partnership. What's next for Amylin?
This biotechnology stock has the brightest growth prospects in Standard &Poor's large-cap biotech universe.
VIDEO ON MSN MONEY
Copyright © 2013 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.
The Market Dispatches column has been discontinued. Here's where to find the latest stock and business news on MSN Money, and the latest from market writer Charley Blaine.
MONEY & POLITICS
Breaking up big banks is an untested solution to the too big to fail problem that attempts to isolate and dismantle large, troubled institutions while protecting the rest of the economy.
If your wallet is running on empty but you still have more shopping to do, we've got you covered. Here are 10 cool kid gifts that won't break the bank.
The IRS is struggling to combat identify thieves who file fraudulent tax returns in the names of older residents who don't need to file.